Contineum Therapeutics (CTNM) Other Accumulated Expenses (2023 - 2025)

Contineum Therapeutics' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $1.2 million for Q3 2025.

• In Q3 2025, Other Accumulated Expenses fell 12.54% year-over-year to $1.2 million; the TTM figure through Sep 2025 stood at $1.2 million (down 12.54% YoY), while the FY2024 annual figure was $3.2 million, up 103.82% from the prior year.
• Other Accumulated Expenses for Q3 2025 stood at $1.2 million, down from $1.7 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.2 million in Q4 2024, with the low at $973000.0 in Q2 2024.
• The 3-year median for Other Accumulated Expenses is $1.6 million (2023), against an average of $1.8 million.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses soared 103.82% in 2024, then declined 12.54% in 2025.
• Contineum Therapeutics' Other Accumulated Expenses stood at $1.5 million in 2023, then jumped by 103.82% to $3.2 million in 2024, then plunged by 62.81% to $1.2 million in 2025.
• Business Quant data shows CTNM's Other Accumulated Expenses at $1.2 million in Q3 2025, $1.7 million in Q2 2025, and $2.5 million in Q1 2025.